Related references
Note: Only part of the references are listed.Low-Dose Nivolumab in Renal Cell Carcinoma: A Real-World Experience
Joseph J. Zhao et al.
ONCOLOGY (2021)
A real-world data of Immune checkpoint inhibitors in solid tumors from India
Vanita Noronha et al.
CANCER MEDICINE (2021)
The Pattern of Care of Use of Nivolumab in Head and Neck Cancers - Audit From a Tertiary Cancer Centre
V. M. Patil et al.
CLINICAL ONCOLOGY (2021)
Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion
G. Le Guyader et al.
EUROPEAN JOURNAL OF CANCER (2020)
Efficacy and safety of low dose immunotherapy in palliative setting of advanced solid tumours
A. Kumar et al.
ANNALS OF ONCOLOGY (2020)
Head and Neck Cancers, Version 2.2020
David G. Pfister et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial
Vijay Patil et al.
Lancet Global Health (2020)
Real-World Nivolumab Wastage and Leftover Drug Stability Assessment to Facilitate Drug Vial Optimization for Cost Savings
Masahide Fukudo et al.
JCO ONCOLOGY PRACTICE (2020)
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
J-P Machiels et al.
ANNALS OF ONCOLOGY (2020)
Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer
Vijay M. Patil et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma
Charlotte Leduc et al.
ESMO OPEN (2018)
Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
Shin Hye Yoo et al.
ESMO OPEN (2018)
ESMO-Magnitude of Clinical Benefit Scale version 1.1
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2017)
Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer
Yan Feng et al.
CLINICAL CANCER RESEARCH (2017)
A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers
Vanita Noronha et al.
SOUTH ASIAN JOURNAL OF CANCER (2017)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck
Vijay Maruti Patil et al.
ORAL ONCOLOGY (2015)
Guidelines for treatment of recurrent or metastatic head and neck cancer
P. Parikh et al.
INDIAN JOURNAL OF CANCER (2014)
Epidemiologic Trends in Head and Neck Cancer and Aids in Diagnosis
Nadarajah Vigneswaran et al.
ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA (2014)
An Evaluation of Treatment Strategies for Head and Neck Cancer in an African American Population
DN Ignacio et al.
WEST INDIAN MEDICAL JOURNAL (2013)
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Julie R. Brahmer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
